title: Increased hexosaminidase activity in antipsychotic-induced extrapyramidal side effects: possible association with higher occurrence in bipolar disorder patients.
abstract: Dystonic movements and Parkinsonism are frequently seen in gangliosidoses and these conditions have been reported to modify dopaminergic plasticity. We investigated whether the activity of hexosaminidase, a type-two ganglioside (GM2) degrading enzyme, correlates with drug-induced extrapyramidal system (EPS) side effects in psychiatric patients. We compared hexosaminidase activity in the lymphocytes of 29 EPS-positive patients, 13 EPS-negative patients, and 30 healthy volunteers. The activities of A and B isoforms of hexosaminidase were higher in EPS-positive patients than EPS-negative patients and healthy controls. Multivariate analysis suggested an interaction with increased B isoform activity and EPS side effects in female bipolar disorder patients. Higher levels of hexosaminidase enzyme activity may explain the frequent occurrence of antipsychotic-induced extrapyramidal side effects in mood disorder patients.
authors.affiliation: Dokuz Eylul University, Medical School, Izmir, Turkey. zeliha.tunca@deu.edu.tr
authors.forename: Zeliha
authors.initials: Z
authors.lastname: Tunca
authors.forename: Halil
authors.initials: H
authors.lastname: Resmi
authors.forename: H Asuman
authors.initials: HA
authors.lastname: Ozkara
authors.forename: Gönenc
authors.initials: G
authors.lastname: Ciliv
authors.forename: Basak
authors.initials: B
authors.lastname: Celtikci
authors.forename: Koksal
authors.initials: K
authors.lastname: Alptekin
authors.forename: Aysegul
authors.initials: A
authors.lastname: Ozerdem
authors.forename: Berna Kivircik
authors.initials: BK
authors.lastname: Akdede
authors.forename: Burak
authors.initials: B
authors.lastname: Baykara
authors.forename: Bilge
authors.initials: B
authors.lastname: Birsoy
authors.forename: Gul
authors.initials: G
authors.lastname: Ergor
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000201:enzymology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006596:Hexosaminidases / Q000378:metabolism*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D008875:Middle Aged; D015999:Multivariate Analysis; D020033:Protein Isoforms / Q000378:metabolism; D012737:Sex Factors
chemical_list: D014150:Antipsychotic Agents; D020033:Protein Isoforms; D006596:Hexosaminidases